[go: up one dir, main page]

AR017819A1 - Sales de metformina, las composiciones farmaceuticas que las contienen, los metodos terapeuticos que aplican dichos compuestos y las combinaciones de talescompuestos con otros agentes terapeuticos - Google Patents

Sales de metformina, las composiciones farmaceuticas que las contienen, los metodos terapeuticos que aplican dichos compuestos y las combinaciones de talescompuestos con otros agentes terapeuticos

Info

Publication number
AR017819A1
AR017819A1 ARP980106198A ARP980106198A AR017819A1 AR 017819 A1 AR017819 A1 AR 017819A1 AR P980106198 A ARP980106198 A AR P980106198A AR P980106198 A ARP980106198 A AR P980106198A AR 017819 A1 AR017819 A1 AR 017819A1
Authority
AR
Argentina
Prior art keywords
compounds
salts
metformine
combinations
apply
Prior art date
Application number
ARP980106198A
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR017819A1 publication Critical patent/AR017819A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se proporcionan sales del agente antidiabético metformina que son sales de metformina de ácidos dibásicos (relacion molar de 2:1), preferentemente fumaratode metformina (2:1) y succinato de metformina (2:1), que podrían emplearse solas o en combinacion con otro agente antihiperglicémico tal como gliburido, parael tratamiento de diabetes. También se proporciona un método para el tratamiento de diabetes que emplea la sal de metformina sola o en combinacion con otroagente antidiabético.
ARP980106198A 1997-12-08 1998-12-07 Sales de metformina, las composiciones farmaceuticas que las contienen, los metodos terapeuticos que aplican dichos compuestos y las combinaciones de talescompuestos con otros agentes terapeuticos AR017819A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98658697A 1997-12-08 1997-12-08

Publications (1)

Publication Number Publication Date
AR017819A1 true AR017819A1 (es) 2001-10-24

Family

ID=25532567

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980106198A AR017819A1 (es) 1997-12-08 1998-12-07 Sales de metformina, las composiciones farmaceuticas que las contienen, los metodos terapeuticos que aplican dichos compuestos y las combinaciones de talescompuestos con otros agentes terapeuticos

Country Status (11)

Country Link
US (1) US6031004A (es)
EP (1) EP1039890B1 (es)
JP (1) JP4278863B2 (es)
AR (1) AR017819A1 (es)
AT (1) ATE261935T1 (es)
AU (1) AU738804B2 (es)
CA (1) CA2312990C (es)
DE (1) DE69822505T2 (es)
ES (1) ES2216335T3 (es)
WO (1) WO1999029314A1 (es)
ZA (1) ZA9811124B (es)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6291495B1 (en) 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US20020028768A1 (en) * 1997-06-18 2002-03-07 Smithkline Beecham P.L.C. Treatment of diabetes with rosiglitazone and insulin
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
US20010049380A1 (en) * 1997-06-18 2001-12-06 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and sulphonylurea
CA2294582C (en) * 1997-06-18 2008-02-12 Smithkline Beecham P.L.C. Treatment of diabetes with thiazolidinedione and metformin
US20020016287A1 (en) * 1997-07-18 2002-02-07 Smithkline Beecham P.L.C. Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
CA2320900C (en) * 1998-03-19 2009-10-27 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
EP1082109B1 (en) * 1998-04-29 2004-06-16 Sumitomo Pharmaceuticals Company, Limited Oral formulation comprising biguanide and an organic acid
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
FR2796551B1 (fr) * 1999-07-23 2003-07-25 Lipha Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant
FR2796940B1 (fr) * 1999-07-26 2005-04-08 Lipha Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant
JP2003520759A (ja) * 1999-08-31 2003-07-08 アンドルックス ファーマスーティカルズ インコーポレーテッド 単位核を有する徐放性錠剤
RU2275915C2 (ru) * 1999-11-03 2006-05-10 Бристол-Маерс Сквибб Компани Способ лечения диабета
US6586438B2 (en) * 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
AU1304601A (en) * 1999-11-11 2001-06-06 Kyorin Pharmaceutical Co. Ltd. Solid preparations for oral use
FR2802813A1 (fr) * 1999-12-23 2001-06-29 Aventis Pharma Sa Association de deoxyfructosazine et d'un antidiabetique de la famille des biguandes
EP1803730A1 (en) * 2000-04-12 2007-07-04 Human Genome Sciences, Inc. Albumin fusion proteins
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
US6296874B1 (en) * 2000-05-01 2001-10-02 Aeropharm Technology Incorporated Core formulation comprising troglitazone and abiguanide
US6270797B1 (en) * 2000-05-18 2001-08-07 Usv Limited Sustained release pharmaceutical composition containing glipizide and method for producing same
FR2809310B1 (fr) * 2000-05-26 2004-02-13 Centre Nat Rech Scient Utilisation de derives de biguanide pour fabriquer un medicament ayant un effet cicatrisant
WO2002012177A1 (en) * 2000-08-03 2002-02-14 Igor Anatolievich Pomytkin Composition of metformin with succinic acid or salts thereof and method for treating diabetes
MXPA03001157A (es) * 2000-08-07 2004-02-17 Ranbaxy Signature Llc Formulacion liquida de metformina.
WO2002028181A1 (en) * 2000-10-02 2002-04-11 Usv Limited Sustained release pharmaceutical compositions containing metformin and method of its production
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
US6790459B1 (en) 2000-11-03 2004-09-14 Andrx Labs, Llc Methods for treating diabetes via administration of controlled release metformin
FR2816841B1 (fr) * 2000-11-22 2004-02-06 Lipha Nouvelles compositions pharmaceutiques a action antidiabetique et leur procede de preparation
FR2818906B1 (fr) 2000-12-29 2004-04-02 Dospharma Association medicamenteuse d'une biguanine et d'un transporteur, par exemple de metformine et d'arginine
FR2818908B1 (fr) * 2000-12-29 2004-04-02 Dospharma Utilisation en tant que medicament d'un compose restituant in vivo des principes actifs
RU2351317C2 (ru) * 2001-01-12 2009-04-10 Сан Фармасьютикал Индастриз Лимитед Система раздельной доставки лекарственных средств
JP4633329B2 (ja) 2001-01-12 2011-02-16 サン・ファーマ・アドバンスド・リサーチ・カンパニー・リミテッド スペーストドラッグデリバリーシステム
KR200249057Y1 (ko) * 2001-03-22 2001-10-19 김진환 뚜껑, 받침대에 합체된 하수역류. 악취방지 장치
PT1377276E (pt) * 2001-04-10 2011-12-30 Sun Pharma Advanced Res Co Ltd Composição de libertação temporizada por pulso
WO2002097038A2 (en) * 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Chemokine beta-1 fusion proteins
WO2002098409A1 (en) * 2001-06-07 2002-12-12 Wyeth Combination therapy for type ii diabetes or syndrome x
EP1435931A2 (en) * 2001-09-28 2004-07-14 Sun Pharmaceuticals Industries Ltd. Dosage form for treatment of diabetes mellitus
IN192180B (es) * 2001-09-28 2004-03-06 Ranbaxy Lab
US7183321B2 (en) * 2001-12-17 2007-02-27 Bristol-Myers Squibb Company Antidiabetic formulation and method
EP2277910A1 (en) 2001-12-21 2011-01-26 Human Genome Sciences, Inc. Albumin fusion proteins
EP1463752A4 (en) * 2001-12-21 2005-07-13 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
DE60219963T2 (de) * 2002-01-25 2008-02-07 Laboratorios Silanes, S.A. De C.V. Pharmazeutische zusammensetzung, die zur glukosekontrolle im blut von patienten mit diabetes typ 2 eingesetzt wird
WO2003068209A1 (en) * 2002-02-14 2003-08-21 Sonus Pharmaceuticals, Inc. Metformin salts of lipophilic acids
US8323692B2 (en) * 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
CA2476201C (en) * 2002-02-21 2009-09-01 Biovail Laboratories Incorporated Modified release formulations of at least one form of tramadol
US20030187074A1 (en) * 2002-03-04 2003-10-02 Javed Hussain Oral compositions for treatment of diabetes
US20030219482A1 (en) * 2002-03-21 2003-11-27 Chaudhari Sunil Sudhakar Multiparticulate compositions for once-a-day administration
US20030224046A1 (en) * 2002-06-03 2003-12-04 Vinay Rao Unit-dose combination composition for the simultaneous delivery of a short-acting and a long-acting oral hypoglycemic agent
AU2002356419A1 (en) 2002-06-17 2003-12-31 Themis Laboratories Private Limited Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
CN100367960C (zh) * 2002-07-11 2008-02-13 武田药品工业株式会社 包衣制剂的制备方法
US8216609B2 (en) * 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US8268352B2 (en) * 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US7959946B2 (en) * 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US20040086566A1 (en) * 2002-11-04 2004-05-06 Alpharma, Inc. Waxy matrix dosage forms
EP1594530A4 (en) 2003-01-22 2006-10-11 Human Genome Sciences Inc HYBRID PROTEINS OF ALBUMIN
EP1608341A1 (en) * 2003-03-21 2005-12-28 Ranbaxy Laboratories, Ltd. Water-soluble tablets of metformin
WO2004108067A2 (en) * 2003-04-03 2004-12-16 Sun Pharmaceutical Industries Limited Programmed drug delivery system
US20050013863A1 (en) * 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
PT1558220E (pt) * 2003-07-24 2010-03-12 Rasendrakumar Jha Composições orais para tratamento da diabetes
FR2858556B1 (fr) * 2003-08-06 2006-03-10 Galenix Innovations Composition pharmaceutique solide dispersible et/ou orodispersible non pelliculee contenant au moins le principe actif metformine, et procede de preparation
EP1510208A1 (en) 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Pharmaceutical composition comprising a combination of metformin and statin
CA2543945A1 (en) * 2003-10-31 2005-05-12 Alza Corporation Compositions and dosage forms for enhanced absorption of 3-amino-n-butyl-phosphinic acid
EP1591114A1 (en) * 2004-03-12 2005-11-02 Fournier Laboratories Ireland Limited Use of metformin and orlistat for the treatment or prevention of obesity
KR100657785B1 (ko) 2005-02-19 2007-04-16 한국유나이티드제약 주식회사 글리메피리드, 메트포르민 및 은행엽엑스를 함유하는 약학적 조성물
MXPA05009633A (es) * 2005-09-08 2007-03-07 Silanes Sa De Cv Lab Composicion farmaceutica estable de glimepirida de liberacion inmediata y metformina de liberacion prolongada.
EP2109447B1 (en) 2007-01-29 2015-06-10 HanAll Biopharma Co., Ltd. N, n- dimethyl imidodicarbonimidic diamide acetate, method for producing the same and pharmaceutical compositions comprising the same
US8076377B2 (en) 2007-09-21 2011-12-13 Hanall Pharmaceutical Company, Ltd. N,N-dimethyl imidodicarbonimidic diamide dicarboxylate, method for producing the same and pharmaceutical compositions comprising the same
WO2009088220A2 (ko) * 2008-01-08 2009-07-16 Hanall Pharmaceutical Company. Ltd Ｎ,ｎ-디메틸 이미도디카르본이미딕 디아미드의 니코틴산염, 그의 제조방법 및 그를 포함하는 약제학적 조성물
FR2928836B1 (fr) * 2008-03-21 2011-08-26 Servier Lab Forme galenique secable permettant une liberation modifiee du principe actif
SI2303838T1 (sl) 2008-06-26 2014-07-31 Laboratorios Silanes, S.A. De C.V. Nova sol metformin glicinata za nadzor glukoze v krvi
US20110021634A1 (en) 2009-06-18 2011-01-27 Patel Pranav Dushyant Processes for preparing metformin hydrochloride
KR20110007984A (ko) * 2009-07-17 2011-01-25 한올바이오파마주식회사 Ｎ,ｎ―디메틸 이미도디카르본이미딕 디아미드의 프로피온산염, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 이를 포함하는 복합제제
US20120135952A1 (en) * 2009-07-17 2012-05-31 Hanall Biopharma Co., Ltd. Butyric acid salt of n,n-dimethyl imidocarbon imidic diamide, method of preparing same, and pharmaceutical compositions and combinations containing same
WO2011049400A2 (ko) * 2009-10-23 2011-04-28 한올바이오파마주식회사 N,n-디메틸 이미도디카르본이미딕 디아미드의 산 부가염을 포함하는 항암용 약제학적 조성물
US8581001B2 (en) 2010-04-16 2013-11-12 Codman & Shurtleff Metformin-cysteine prodrug
WO2011154975A2 (en) 2010-06-08 2011-12-15 Cadila Healthcare Limited Pharmaceutical compositions of metformin
US8440723B2 (en) * 2011-05-11 2013-05-14 Banavara L. Mylari Metformin salts of salicylic acid and its congeners
CN102391160A (zh) * 2011-11-23 2012-03-28 黎波 二甲双胍与2，5-二羟基苯磺酸盐以及二甲双胍与2，5-二羟基苯磺酸盐的复方组合物
WO2014008374A2 (en) * 2012-07-06 2014-01-09 Thetis Pharmaceuticals Llc Combination therapies comprising metformin salts and antihyperglycemia agents or antihyperlipidemia agents
BR112015000368A2 (pt) * 2012-07-10 2017-06-27 Thetis Pharmaceuticals Llc forma de tri-sais de metformina
US9815777B2 (en) 2013-09-22 2017-11-14 Jiva Pharma, Inc. Metformin salts to treat Type2 diabetes
WO2015183794A1 (en) 2014-05-27 2015-12-03 City Of Hope Tgr5 agonist complexes for treating diabetes and cancer
WO2017168245A1 (en) 2016-04-01 2017-10-05 University Of Limerick Pharmaceutical compositions and methods for the treatment of diabetes
WO2017195086A1 (en) * 2016-05-10 2017-11-16 Sarath Kumar Kamavarapu Salts of n,n-dimethylbiguanide and preparation methods thereof
WO2018034627A1 (en) 2016-08-18 2018-02-22 İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi Pharmaceutical composition of antidiabetic tablet
CA3103617A1 (en) 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for lowering blood sugar with a metformin pharmaceutical composition
EP4045520A1 (en) 2019-10-16 2022-08-24 Bayer Aktiengesellschaft Methods for the improved formation of acarbose
CN113105367B (zh) 2021-03-30 2022-08-02 广州大学 一类二甲双胍盐及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) * 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
FR2037002A1 (en) * 1969-04-30 1970-12-31 Roques Bernard N-substd biguanide pamoic acid salts prepn
FR2320735A1 (fr) * 1975-08-12 1977-03-11 Dabis Georges Composition anti-cellulite
FR2611500B1 (fr) * 1987-03-06 1990-05-04 Lipha Emploi de derives du biguanide dans la preparation de medicaments
JPS648237A (en) * 1987-06-29 1989-01-12 Mitsubishi Electric Corp Copper alloy for terminal and connector
IT1276130B1 (it) * 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
FR2774591B1 (fr) * 1998-02-12 2000-05-05 Lipha Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
CA2320900C (en) * 1998-03-19 2009-10-27 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method

Also Published As

Publication number Publication date
AU1602699A (en) 1999-06-28
WO1999029314A1 (en) 1999-06-17
JP2001525361A (ja) 2001-12-11
JP4278863B2 (ja) 2009-06-17
EP1039890B1 (en) 2004-03-17
EP1039890A1 (en) 2000-10-04
US6031004A (en) 2000-02-29
ES2216335T3 (es) 2004-10-16
ZA9811124B (en) 2000-06-05
ATE261935T1 (de) 2004-04-15
CA2312990C (en) 2008-04-29
EP1039890A4 (en) 2001-04-04
DE69822505T2 (de) 2005-01-20
AU738804B2 (en) 2001-09-27
CA2312990A1 (en) 1999-06-17
DE69822505D1 (de) 2004-04-22

Similar Documents

Publication Publication Date Title
AR017819A1 (es) Sales de metformina, las composiciones farmaceuticas que las contienen, los metodos terapeuticos que aplican dichos compuestos y las combinaciones de talescompuestos con otros agentes terapeuticos
NO873244D0 (no) Legemiddel.
ES2032899T3 (es) Agente cosmetico para aplicacion externa y su uso.
ATE31625T1 (de) Pharmazeutisches mittel zur behandlung des diabetes mellitus.
ATE113834T1 (de) Zusammensetzung zur behandlung der schizophrenie.
PT90764A (pt) Processo para a preparacaode um produto farmaceutico compreendendo um estrogenio e um anti-estrigenio e de composicoes farmaceuticas que os contem
ES2157424T3 (es) Esteres de acido 5-aminolevulinico como agentes fotosensibilizantes en fotoquimioterapia.
ES2083593T3 (es) Compuestos y metodos para inhibir la expresion de genes.
ES2159591T3 (es) Composicion de liberacion controlada.
ES2134804T3 (es) Uso de un compuesto generador de oxido nitrico para prevenir daño neuronal.
ES2160640T3 (es) Nuevos (r)-5-carbamoil-8-fluoro-3-amino disustituido en n,n-3,4-dihidro-2h-1-benzopiranos.
UY25713A1 (es) Método para tratar diabetes empleando un inhibidor ap2 y combinación.
ES2116421T3 (es) Composiciones que contienen aminoacidos mono o polihidroxilados para el tratamiento de la diabetes no insulino-dependiente.
AR008305A1 (es) Guanidinas de acidos alquenil-carboxilicos sustituidos con fenilo, procedimientos para su preparacion, su utilizacion como medicamento o agente dediagnostico, asi como un medicamento que las contiene
ES2168395T3 (es) Nueva formulacion antitrombotica, procedimiento para su preparacion y utilizacion de la misma.
ES2178779T3 (es) Nuevas amidas de acidos de piridil alcanos como agentes citoestaticos e inmunosupresores.
ES2170813T3 (es) Acidos 2,2-dicloroalcanocarboxilicos, proceso para su preparacion, medicamentos que los contienen y su uso para tratar la resistencia a la insulina.
ES2055035T3 (es) Un proceso para la preparacion de un glicosido de antraciclina.
ES2183332T3 (es) Aminoacidos biciclicos aromaticos.
ES2032888T3 (es) Productos conservados para la limpieza del cabello y el cuerpo y utilizacion de una combinacion de sustancias conservantes.
AR006401A1 (es) Compuestos de pirrolopirrolona, una composicion farmaceutica que los contiene, su uso en la fabricacion de un medicamento y en terapia, procesospara su preparación y compuestos intermediarios para dichos procesos.
ES2129802T3 (es) Composicion para el tratamiento de agua y el saneamiento de suelos.
ATE140382T1 (de) Haarpflegemittel
ATE108658T1 (de) Verwendung von tetracycline zur herstellung eines arzneimittels zum herabsetzen des augendrucks.
ATE120180T1 (de) 4,5-dihydroxy und 4,5,8-trihydroxy-9,10-dioxo-2- anthracencarbonsäure-dikohlensäureester und urethane mit therapeutischer wirkung.